{"entity":{"id":"nct06549751","kind":"trial","name":"MT-601 Administered To Patients With Locally Advanced Unresectable or Metastatic Pancreatic Cancer","aka":[],"tldr":"A phase 1 trial of MT-601 run by Marker Therapeutics, Inc., not yet recruiting.","summary":"MT-601 Administered To Patients With Locally Advanced Unresectable or Metastatic Pancreatic Cancer is a phase 1 interventional study registered as NCT06549751 by Marker Therapeutics, Inc., with 38 participants planned, started 2026-07-16. Conditions recorded: Pancreas Cancer, Pancreatic Cancer Metastatic and Pancreatic Cancer (Unresectable). Interventions recorded: MT-601 dose 200 million cells, MT-601 dose 400 million cells, MT-601 dose 800 million cells and MT-601 dose 1200 million cells.","status":"planned","asOf":"2026-11-03","links":[{"label":"ClinicalTrials.gov NCT06549751","url":"https://clinicaltrials.gov/study/NCT06549751"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["pancreatic","metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["mt-601"],"companies":["marker-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06549751","phase":"1","setting":"A Phase 1 Study With Expansion of Patient-Derived Multi-Tumor-Associated Antigen Specific T Cells (MT-601) Administered To Patients With Locally Advanced Unresectable or Metastatic Pancreatic Cancer (PANACEA)","sponsor":"Marker Therapeutics, Inc.","enrolled":38,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06549751/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"drug":[{"id":"mt-601","kind":"drug","name":"MT-601","route":"/drugs/mt-601/"}],"company":[{"id":"marker-therapeutics","kind":"company","name":"Marker Therapeutics","route":"/companies/marker-therapeutics/"}]}}